Skip to search formSkip to main contentSkip to account menu

ABT 229

Known as: ABT-229 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
OBJECTIVE To investigate the effect of interstitial cells of Cajal (ICC) on contraction of intestinal tract smooth muscle induced… 
2006
2006
Gastroesophageal reflux disease (GERD) occurs when stomach contents flow into the esophagus. GERD sufferers often complain of a… 
2002
2002
ABT‐229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in… 
2001
2001
Introduction—Erythromycin, a motilin agonist, is a potent prokinetic. ABT-229 is a specific motilin agonist that dose dependently… 
2000
2000
We investigated the in vivo and in vitro locus of actions of prokinetics: motilin, erythromycin, and ABT-229. The test substances… 
1999
1999
1. Erythromycin lactobionate caused a concentration‐ dependent inhibition of nerve‐mediated contractions of the longitudinal… 
1998
1998
In our quest toward the discovery of highly potent and acid-stable motilides, novel 4"-deoxy derivatives of 9-deoxo-6, 9…